Human IgG1 Kappa-AP

Cat. No.
0151K-04  
Size
1.0 mL  
Price (USD)
$140.00 
Source Human myeloma serum
Format/Conjugate AP (Alkaline Phosphatase)
Buffer Formulation Supplied in a stock solution of 50 mM Tris/1 mM MgCl2/50% glycerol, pH 8.0, containing NaN3 as a preservative
Volume 1.0 mL
Storage & Handling Store at 2-8°C
Please refer to product specific SDS
Applications
Quality tested applications for relevant formats include -
ELISA 1,2
FLISA
Other referenced applications for relevant formats include -
Flow Cytometry 8,9
Immunoprecipitation 3
In vitro control 4-6
In vivo control 1,7
Stimulation (Fc mediated) 10
Blocking 6
Surface Plasmon Resonance 1
Recommended Dilutions Please refer to product specific Technical Bulletin
  • ELISA plate was coated with Mouse Anti-Human IgG1 Hinge-UNLB (SB Cat. No. 9052-01), Mouse Anti-Human IgG2 Fc-UNLB (SB Cat. No. 9060-01), Mouse Anti-Human IgG3 Hinge-UNLB (SB Cat. No. 9210-01), Mouse Anti-Human IgG4 pFc’-UNLB (SB Cat. No. 9190-01), Mouse Anti-Human IgA1-BIOT (SB Cat. No. 9130-01), Mouse Anti-Human IgA2-UNLB (SB Cat. No. 9140-01), Mouse Anti-Human IgD-UNLB (SB Cat. No. 9030-01), Mouse Anti-Human IgE Fc-UNLB (SB Cat. No. 9160-01), Mouse Anti-Human IgM-UNLB (SB Cat. No. 9020-01), Mouse Anti-Human Kappa-UNLB (SB Cat. No. 9230-01), and Mouse Anti-Human Lambda-UNLB (SB Cat. No. 9180-01). Serially diluted Human IgG1 Kappa-AP (SB Cat. No. 0151K-04) was captured and quantified.

ELISA plate was coated with Mouse Anti-Human IgG1 Hinge-UNLB (SB Cat. No. 9052-01), Mouse Anti-Human IgG2 Fc-UNLB (SB Cat. No. 9060-01), Mouse Anti-Human IgG3 Hinge-UNLB (SB Cat. No. 9210-01), Mouse Anti-Human IgG4 pFc’-UNLB (SB Cat. No. 9190-01), Mouse Anti-Human IgA1-BIOT (SB Cat. No. 9130-01), Mouse Anti-Human IgA2-UNLB (SB Cat. No. 9140-01), Mouse Anti-Human IgD-UNLB (SB Cat. No. 9030-01), Mouse Anti-Human IgE Fc-UNLB (SB Cat. No. 9160-01), Mouse Anti-Human IgM-UNLB (SB Cat. No. 9020-01), Mouse Anti-Human Kappa-UNLB (SB Cat. No. 9230-01), and Mouse Anti-Human Lambda-UNLB (SB Cat. No. 9180-01). Serially diluted Human IgG1 Kappa-AP (SB Cat. No. 0151K-04) was captured and quantified.
 
References
1. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-52. (ELISA, in vivo control, Surface plasmon resonance)
2. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun. 2009;33:270-4. (ELISA)
3. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241-56. (IP)
4. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869-80. (In vitro control)
5. Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-18. (In vitro control)
6. Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015;3:54. (In vitro control, Block)
7. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differ. 2015;22:1477-88. (In vivo control)
8. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol. 2015;89:512-22. (FC)
9. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54. (FC)
10. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Sci Transl Med. 2016;8:365ra158. (Stim)
11. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82:5219-26. (Mass spectrometry)